OAE0205 'Endeavor to reach the furthest behind first': promoting HIV prevention services using social media intervention in the era of COVID 19 among FSW in Benue StateOral abstract session with live Q&AOptimizing HIV services (prevention, testing and/or treatment) in the COVID-19 era
OAE0302 The effect of a conditional cash transfer program on AIDS morbidity and mortality among the poorest: a quasi-experimental study of a cohort of 22.7 million BraziliansOral abstract session with live Q&ASocial protection: New evidence and programmatic lessons
OAE0303 Cost-effectiveness of broadly neutralizing antibodies for HIV prophylaxis for all infants born in high-burden settingsOral abstract session with live Q&AEconomic evaluation and affordability assessments
OAE0304 The relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis: a modelled economic evaluation and threshold analysis in South Africa based on the HPTN 083 and 084 trialsOral abstract session with live Q&AEconomic evaluation and affordability assessments
OAE0305 Variation in average unit prices (2020) of antiretroviral drugs in generic accessible low- and middle-income countriesOral abstract session with live Q&AFinancing HIV, hepatitis and STI testing and drug access: The economics of generics and differential pricing structures
OAE0402 Is local production of HIV commodities a feasible strategy for improving domestic ownership and financial sustainability of HIV epidemiological control in low- and middle-income settings?Oral abstract session with live Q&AApproaches to achieving sustainability, including sustainable financing for civil society
OAE0403 Quantifying the health and economic impact of voluntary licensing of HIV medicines in low- and middle-income countries: putting numbers on additional uptake, deaths averted, and money saved by MPP licencesOral abstract session with live Q&AFinancing HIV, hepatitis and STI testing and drug access: The economics of generics and differential pricing structures
OAE0404 Estimated costs to address unmet financial needs for HIV pre-exposure prophylaxis, United States, 2018Oral abstract session with live Q&ANational financing analyses and financing mechanisms for HIV, hepatitis and STI programmes and services
OAE0405 Thailand national PrEP program: moving towards sustainabilityOral abstract session with live Q&AImplementation science of scaling up prevention (including PrEP)
OAE0406 The economic returns of achieving the 2021-2030 AIDS targets to end the AIDS epidemic by 2030Oral abstract session with live Q&AEconomic evaluation and affordability assessments
91 - 100 of 2486 items